Thyroid dysfunction is recognized in the newborns of mothers affected by Graves' disease during pregnancy. We describe the development of concurrent hyperthyroidism and hypothyroidism in the twin infants of a mother with Graves' disease diagnosed during pregnancy.
Introduction
Graves' disease complicates one out of every 1000 pregnancies. 1 Mothers are typically treated with propylthiouracil (PTU) to maintain euthyroid status. 2 We report a case in which the twins of a mother with Graves' disease developed unexpectedly different manifestations of thyroid function.
Case summary
Male twins of a dichorionic, diamniotic pregnancy were born at 31 weeks gestation to a 27-year-old gravida 5, para 1 mother with Graves' disease diagnosed in the second trimester; total maternal T3 was 10.68 nmol/l (normal, 1.00 to 2.53 nmol/l) at diagnosis. PTU was started immediately. TSH 1 month before delivery was <0.01 mIU/l (normal, 0.45 to 4.50 mIU/l), indicating inadequate disease control. Mother had an elevated thyroid stimulating immunoglobulin (TSI) level measured 1 month before delivery (143% of baseline cAMP production; normal, <125% of baseline). The twins were delivered via cesarean section after premature rupture of membranes and the development of chorioamnionitis.
The postnatal course for both twins was unremarkable. Birth weight for twin A and twin B was 1865 and 1445 g, respectively.
On day of life 3, twin A had a total thyroxine of 39.90 nmol/l (normal, 105.53 to 256.11 nmol/l), a free thyroxine of 7.70 pmol/l (normal, 25.74 to 63.06 pmol/l), and a TSH of 33.92 mIU/l (normal, 0.13 to 9.20 mIU/l), consistent with hypothyroidism. Similarly, twin B had a total thyroxine of 32.20 nmol/l, a free thyroxine of 7.70 pmol/l, and a TSH of 61.20 mIU/l. Free thyroxine was measured using the enzyme immunoassay method. No therapy was initiated at this time.
On day of life 4, twin A developed a free thyroxine level of 6.40 pmol/l and a TSH of 41.90 mIU/l consistent with continued hypothyroidism, whereas twin B had a free thyroxine of 54.10 pmol/l and a TSH of 3.67 mIU/l, consistent with hyperthyroidism. Twin B manifested clinical signs of hyperthyroidism including tachycardia, hypertension and jitteriness; neither twin had a goiter. At this time, twin A was started on levothyroxine 0.025 mg daily (13.7 mcg/kg/day) and twin B on PTU 3 mg every 8 h (6.2 mg/kg/day).
At 8 days of age, twin B had a TSI 252% of baseline cAMP production whereas that of twin A was 297% of baseline. TSH-binding inhibitory immunoglobulins (TBII) were not measured in the mother or in the twins' cord blood. Two weeks after starting PTU, twin B became hypothyroid and PTU was discontinued. One week after starting levothyroxine, twin A became and remained hyperthyroid despite discontinuation of levothyroxine, so PTU was initiated. At the time of discharge, twin A was receiving PTU, whereas twin B required no medications. At 1 year of age both twins were euthyroid without medication.
Discussion
In Graves' disease, TSI and PTU cross the placenta, potentially resulting in neonatal thyroid dysfunction. 3 Hyperthyroidism from transplacental passage of TSI occurs in 1 to 10% of infants born to mothers with Graves' disease; these infants often require thyroid suppression for several weeks until maternal TSI clearance. 4 TSI measurements in the hyperthyroid pregnant mother are used to prognosticate neonatal hyperthyroidism. 5 Hypothyroidism may result from maternal PTU treatment; this is more transient and typically requires several weeks of levothyroxine. Neonatal hypothyroidism in the setting of maternal autoimmune thyroid disease may also be secondary to blocking antibodies against the TSH receptor (TSH-receptor stimulating blocking antibody) 6 or another group of antibodies known as TBII. 7 The differential clinical presentations of the twins after delivery was unexpected. Although initially hypothyroid, why the twins diverged clinically later remains unclear. Similar divergent expression of hyperthyroidism and hypothyroidism in twins has been noted previously in both newborns and adults. [8] [9] [10] If identical twinning occurred, one would expect the transplacental passage, uptake and metabolism of TSI and PTU in these twins to be similar. However, neither HLA typing nor detailed pathologic investigation of the placenta was performed in these infants and the reason for their size discordance is unknown.
Prematurity and the subsequent postnatal course influence the establishment of a normal thyroid axis. The sick or extremely premature may have derangements of the hypothalamicpituitary-thyroid axis, with most demonstrating low TSH, T3 and T4 2 . However, both twins had a benign and nearly identical clinical course, and their initial hypothyroidism was accompanied by a high TSH, indicating a robust hypothalamic-pituitary-thyroid axis.
Twin A had a lower measured TSI level than twin B, but on a per kilogram basis, his TSI level was greater than that of twin B. It is therefore plausible that twin A had a greater proportion of TBII, which led to clinical hypothyroidism or, at the least, the absence of hyperthyroidism. Neutralization of TSI by TBII has been reported.
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Another concept is a novel mechanism of transient hypothyroidism, recognized by Matsuura et al. 12, 13 in 1988. Fetal hyperthyroidism (from transplacental passage of T4) in utero owing to poorly controlled or undiagnosed maternal Graves' disease causes suppression of the neonatal pituitary-thyroid axis, with low TSH and total T4 values. Although both patients had initially high TSH, the changes in levels of TSH, T4 and free T4 after the initiation of treatment likely represents overcorrection of the hypothyroid or hyperthyroid state and clearance of maternal TSI and TBII from the twins' blood.
In summary, we present a case of premature twins born to a mother with Graves' disease diagnosed during pregnancy. Both had initial biochemical manifestations of hypothyroidism, whereas one twin progressed to overt hyperthyroidism requiring PTU treatment and the second twin remained biochemically hypothyroid and required brief thyroid replacement therapy. This case illustrates the complex interactions dictating the establishment of normal thyroid function in newborns, and also the importance of evaluating thyroid function in infants born to thyrotoxic mothers early in the neonatal period and instituting appropriate therapy. Frequent follow-up of infants receiving medications directed toward the thyroid axis is warranted to ensure that proper correction of thyroid function is achieved.
